Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ICUI 
ICU Medical Inc (ICUI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ICUI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $186.2
1 Year Target Price $186.2
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.99% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.33B USD | Price to earnings Ratio - | 1Y Target Price 186.2 |
Price to earnings Ratio - | 1Y Target Price 186.2 | ||
Volume (30-day avg) 6 | Beta 0.89 | 52 Weeks Range 117.92 - 196.26 | Updated Date 07/6/2025 |
52 Weeks Range 117.92 - 196.26 | Updated Date 07/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.87% | Operating Margin (TTM) 4.89% |
Management Effectiveness
Return on Assets (TTM) 1.79% | Return on Equity (TTM) -4.62% |
Valuation
Trailing PE - | Forward PE 20.66 | Enterprise Value 4644162747 | Price to Sales(TTM) 1.38 |
Enterprise Value 4644162747 | Price to Sales(TTM) 1.38 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 16.67 | Shares Outstanding 24611900 | Shares Floating 23848229 |
Shares Outstanding 24611900 | Shares Floating 23848229 | ||
Percent Insiders 3.04 | Percent Institutions 101.79 |
Upturn AI SWOT
ICU Medical Inc
Company Overview
History and Background
ICU Medical Inc. was founded in 1984. Initially focused on needlefree IV connectors, it expanded through acquisitions and product development to become a leader in infusion therapy and critical care technologies. A significant milestone was the acquisition of Hospira Infusion Systems from Pfizer in 2017.
Core Business Areas
- Infusion Systems: ICU Medical offers a comprehensive range of infusion pumps, dedicated administration sets, and solutions designed for medication delivery, fluid management, and patient monitoring.
- IV Solutions: This segment provides a variety of IV solutions used for hydration, drug delivery, and nutritional support.
- Medication Delivery: Offers a range of products for safe and efficient medication delivery, including closed system transfer devices (CSTD) and other safety-related technologies.
Leadership and Structure
Vivek Jain serves as the Chief Executive Officer. The company has a traditional corporate structure with departments covering R&D, manufacturing, sales, marketing, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- IV Sets: IV sets are a core offering, with ICU Medical holding a significant portion of the market for certain specialized sets. Competitors include Baxter, B. Braun, and Smiths Medical. Market share data is fragmented and varies by specific IV set category.
- Infusion Pumps: ICU Medical's infusion pumps are a key revenue driver. They compete with Baxter, B. Braun, and Medtronic in this space. Market share data is challenging to obtain precisely, but ICU Medical is a major player.
- Closed System Transfer Devices (CSTD): These devices protect healthcare workers from hazardous drugs during compounding and administration. ICU Medical is a top competitor along with BD and Equashield. Market share data is fragmented and varies by specific region.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by an aging population, increasing chronic diseases, and technological advancements. Demand for infusion therapy and medication delivery systems continues to rise.
Positioning
ICU Medical holds a strong position in the infusion therapy market, particularly after the Hospira acquisition. Their competitive advantages include a broad product portfolio, established customer relationships, and a focus on safety and innovation.
Total Addressable Market (TAM)
The TAM for infusion therapy and related products is estimated to be in the tens of billions of dollars globally. ICU Medical is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Established customer relationships
- Strong presence in the infusion therapy market
- Focus on safety and innovation
Weaknesses
- Dependence on key products
- Exposure to regulatory changes
- Integration challenges from acquisitions
- High debt level
Opportunities
- Expanding into emerging markets
- Developing new and innovative products
- Acquiring complementary businesses
- Growing demand for home infusion therapy
Threats
- Intense competition
- Pricing pressures
- Product recalls
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- BAX
- B Braun (Private)
- BDX
Competitive Landscape
ICU Medical competes with larger players like Baxter and B. Braun. Its advantages include a specialized focus and a strong presence in certain market segments. Disadvantages may include limited scale compared to larger competitors.
Major Acquisitions
Hospira Infusion Systems
- Year: 2017
- Acquisition Price (USD millions): 900
- Strategic Rationale: Expanded ICU Medical's product portfolio and market share in infusion therapy.
Growth Trajectory and Initiatives
Historical Growth: ICU Medical has experienced growth through acquisitions and organic expansion.
Future Projections: Future projections are based on analyst estimates, which are subject to change.
Recent Initiatives: Recent initiatives include product launches, strategic partnerships, and cost-reduction programs.
Summary
ICU Medical is a significant player in the infusion therapy market with a broad product portfolio. The Hospira acquisition strengthened its position, but integration and debt management remain challenges. Competition and regulatory changes pose ongoing threats, while emerging markets offer growth opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICU Medical Inc
Exchange NASDAQ | Headquaters San Clemente, CA, United States | ||
IPO Launch date 1992-03-31 | CEO & Chairman of the Board Mr. Vivek Jain | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15000 | Website https://www.icumed.com |
Full time employees 15000 | Website https://www.icumed.com | ||
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.